CPL @1111 (65.4%) on 25-jun-2018 [ "various medications , such as _" "_ was clastogenic" "_ is usually taken once a day" "CAUTION Stop taking _" ] using gemifloxacin
SEAL @290 (93.8%) on 07-jun-2011 [ 1234 ] using gemifloxacin
CMC @307 (99.8%) on 20-jun-2011 [ SUFFIX=cin 3.13710 SUFFIX=in 2.89045 LASTSUFFIX=in 2.17134 CHARS 1.58296 LASTSUFFIX=cin 1.06347 SUFFIX=acin 0.96943 LASTSUFFIX=acin 0.85197 POS=NNS -1.18162 FULL_POS=NNS -2.77137 WORDS -3.01744 ] using gemifloxacin
CPL @1107 (93.7%) on 24-may-2018 [ "multiple doses of _" "safety profile of _" "possible side effects of _" "treatment with _" "information comparing use of _" "usual dose of _" "vitro activities of _" "common side effects of _" "course of oral _" "Breast-feeding—It is not known whether _" "MIC for _" "Common side effects of _" "MIC of _" "pharmacokinetics of _" "cross-resistance between _" "doses of _" "Drug interactions with _" "carcinogenic potential of _" "higher doses of _" "average doses of _" "tablet contains _" "patients treated with _" "D-day course of _" "specific information comparing use of _" "comparing use of _" "clinical efficacy of _" "antibiotics , including _" "side effects , stop taking _" "patients receiving _" "therapy with oral _" "antibiotics such as _" "absorption of oral _" "antibacterial agents , including _" "protein binding of _" "effects , stop taking _" "elimination half-life of _" "side effects of _" "you are allergic to _" "quinolones , including _" "vitro activity of _" "Plasma concentrations of _" "_ is the active ingredient" "oral administration of _" "you are taking _" "you stop taking _" "dose of _" "medications such as _" "drug , generic _" "clinical trials with _" "_ is an antibiotic" "drugs like _" ] using gemifloxacin
relations
NELL has only weak evidence for items listed in grey